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Background: We assessed the short-term efficacy and safety of aztreonam lysine for inhalation
(AZLI [an aerosolized monobactam antibiotic]) in patients with cystic fibrosis (CF) and Pseudo-
monas aeruginosa (PA) airway infection.
Methods: In this randomized, double-blind, placebo-controlled, international study (AIR-CF1
trial; June 2005 to April 2007), patients (n  164; > 6 years of age) with FEV1 > 25% and < 75%
predicted values, and no recent use of antipseudomonal antibiotics or azithromycin were treated
with 75 mg of AZLI (three times daily for 28 days) or placebo (1:1 randomization), then were
monitored for 14 days after study drug completion. The primary efficacy end point was change
in patient-reported respiratory symptoms (CF-Questionnaire-Revised [CFQ-R] Respiratory
Scale). Secondary end points included changes in pulmonary function (FEV1), sputum PA density,
and nonrespiratory CFQ-R scales. Adverse events and minimum inhibitory concentrations of
aztreonam for PA were monitored.
Results: After 28 days of treatment, AZLI improved the mean CFQ-R respiratory score (9.7
points; p < 0.001), FEV1 (10.3% predicted; p < 0.001), and sputum PA density ( 1.453 log10
cfu/g; p < 0.001), compared with placebo. Significant improvements in Eating, Emotional Function-
ing, Health Perceptions, Physical Functioning, Role Limitation/School Performance, and Vitality
CFQ-R scales were observed. Adverse events were consistent with symptoms of CF lung disease and
were comparable for AZLI and placebo except the incidence of “productive cough” was reduced by
half in AZLI-treated patients. PA aztreonam susceptibility at baseline and end of therapy were
similar.
Conclusions: In patients with CF, PA airway infection, moderate-to-severe lung disease, and no recent
use of antipseudomonal antibiotics or azithromycin, 28-day treatment with AZLI significantly
improved respiratory symptoms and pulmonary function, and was well tolerated.
Trial registration: Clinicaltrials.gov Identifier: NCT00112359 (CHEST 2009; 135:1223–1232)
Key words: aztreonam; cystic fibrosis; inhaled antibiotics; patient-reported outcomes; Pseudomonas; respiratory symptoms
Abbreviations: AZLI  aztreonam lysine for inhalation; CF  cystic fibrosis; CFQ-R  Cystic Fibrosis Questionnaire-
revised; CFQ-R-Respiratory  Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale; CI  confidence interval;
MCID  minimal clinically important difference; MIC  minimum inhibitory concentration; MIC50  minimum inhibitory
concentration inhibiting the growth of 50% of Pseudomonas aeruginosa isolates; MIC90  minimum inhibitory concentration
inhibiting the growth of 90% of Pseudomonas aeruginosa isolates; PA  Pseudomonas aeruginosa; PRO  patient-reported
outcome; TIS  tobramycin inhalation solution
C linical management of cystic fibrosis (CF) hasimproved during the past 15 years. Increased
standardization of care and a focus on maintenance
therapies, including nutrition, combined with the
introduction of dornase alfa in 1993, tobramycin
inhalation solution (TIS) in 1998, and the wide-
spread long-term use of azithromycin (a macrolide
antibiotic) have been associated with an approximate
8-year increase in median predicted survival age
(increase from 1990 to 2005 to 36.5 years of age) and
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a 10% increase in median FEV1 percent predicted
(from 1990 to 2005).1–5 However, a sizable propor-
tion of patients with CF do not receive long-term TIS
or macrolide therapy. In 2005, among US patients in
a national registry who were  6 years of age with
CF and Pseudomonas aeruginosa (PA) airway infec-
tion, 42% of patients were not receiving long-term
TIS therapy, and 46% of patients who were eligible
for long-term macrolide therapy were not receiving
it.1 Lack of compliance likely further reduces the
number of patients receiving therapy; in one recent
study, dosing compliance ranged from 51% (older
patients) to 73% (younger patients).6 The reasons
underlying the lack of treatment may include a lack
of clinical response or drug availability, patient or
physician preference, or drug intolerance. Additional
antimicrobial treatment options are needed for treat-
ing chronic PA airway infection and may improve the
health of these less intensively treated patients.
Aztreonam lysine for inhalation (AZLI) is an aero-
solized formulation of the monobactam antibiotic,
aztreonam, and lysine.7 The IV aztreonam formula-
tion contains arginine, which can cause airway in-
flammation after long-term inhalation in patients
with CF.8,9 In a previous study,10 AZLI increased the
time to the need for additional inhaled or IV anti-
pseudomonal antibiotics to treat symptoms indica-
tive of pulmonary exacerbation; enrolled patients
were generally compliant with current guidelines for
CF care. In contrast, the study we report herein
included patients receiving less maintenance therapy
than currently recommended.11 Patients had not
recently received therapy with antipseudomonal an-
tibiotics, azithromycin, or aerosolized hypertonic sa-
line solution. The study hypothesis was that treatment
with AZLI, when compared with placebo, would pro-
duce a clinically significant improvement in patient-
reported respiratory symptoms. The primary efficacy
end point was the change in clinical symptoms, mea-
sured with the Cystic Fibrosis Questionnaire-Revised
Respiratory Symptom Scale (CFQ-R-respiratory). The
Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a
validated, health-related, quality-of-life measure meeting
the most recent US Food and Drug Administration draft
guidelines on patient-reported outcomes (PROs).12–15
Materials and Methods
Study Design
This randomized, double-blind, placebo-controlled, study was
conducted at 53 CF centers (in Australia, Canada, New Zealand,
and the United States; June 2005 to April 2007). At baseline (day
0), patients were stratified by CF disease severity (moderate
disease, FEV1  50% to  75% predicted; severe disease,
FEV1  25% to  50% predicted; measured at screening) and
randomly assigned to 28 days of treatment with 75 mg of AZLI or
placebo (randomized 1:1; administered three times daily). Pa-
tients were monitored at midtreatment (day 14), at treatment end
(day 28), and at study end (day 42) [Fig 1]. Randomization was
accomplished through a Web-based system using a computer-
generated randomization schedule. This centralized randomiza-
tion was stratified by baseline disease severity (FEV1  50%
or  50% predicted) and employed a block size of 4.
A physical examination was performed at screening. Spirom-
etry, using American Thoracic Society standards16 was performed
at every visit, before and 30 min after any treatment. FEV1
percent predicted values were calculated using the equation of
Knudson et al.17
AZLI (75 mg of aztreonam, 52.5 mg of lysine monohydrate) or
placebo (5 mg of lactose), diluted in 1 mL of a 0.17% NaCl
solution, were administered with a nebulizer (eFlow Electronic
Nebulizer; PARI Innovative Manufacturers; Midlothian, VA).18
Patients self-administered a short-acting 2-agonist 15 min be-
fore spirometry measurements were made and study medication
was administered at clinic visits, and self-administered a 2-
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agonist before administering the study medication at home
(within 2 h before dosing for short-acting agents, or 30 min to 8 h
before dosing for long-acting agents). Patients continued any
prescribed bronchodilator use, excluding a 4-h period before
study visits. Study medication was dispensed at baseline; used/
unused vials were subsequently collected to assess treatment
compliance.
This study was conducted in compliance with the Declaration
of Helsinki, the International Conference on Harmonisation
guideline for Good Clinical Practices, and the applicable regula-
tions for each participating country. Institutional review boards
(in the United States) and ethics committees (in Canada, Austra-
lia, and New Zealand) approved the study for each site, and all
patients or their guardians provided written informed consent or
assent prior to undergoing any study procedures.
Study Population
Patients enrolled into the study were  6 years of age with a
documented CF diagnosis, and had moderate-to-severe lung
disease (FEV1  25% to  75% predicted), arterial oxygen
saturation  90% on room air (at screening), the ability to
perform reproducible pulmonary function tests, and PA airway
infection (documented at screening or twice within previous year,
including once within the previous 3 months) without regard to
PA susceptibility to aztreonam. Exclusion criteria included recent
(ie, day 28 to screening) administration of inhaled, IV, or oral
antipseudomonal antibiotics, azithromycin, or aerosolized hyper-
tonic saline solution; current oral corticosteroid use equivalent to
 10 mg of prednisone daily; airway cultures yielding Burkhold-
eria cepacia complex (previous 2 years); daily continuous oxygen
supplementation or  2 L/min at night; monobactam antibiotic
hypersensitivity; intolerance to inhaled short-acting 2-agonists;
recent changes in antimicrobial, bronchodilator, antiinflamma-
tory, or corticosteroid medications, or physiotherapy technique/
schedule; lung transplantation; new findings on chest radiograph
at screening or in the previous 90 days; aspartate aminotransfer-
ase or alanine aminotransferase levels more than five times the
upper limit of normal (at screening), or serum creatinine levels more
than two times the upper limit of normal (at screening); pregnancy;
lactation; or, in the opinion of the investigator, medical or psychiatric
illness interfering with study participation. Patients were not per-
mitted to use other antipseudomonal antibiotics or azithromycin
during the study or during the 14-day follow-up period, unless
required for the treatment of worsening symptoms.
Efficacy Measures
The CFQ-R was administered at baseline and at every visit
thereafter. Unless noted, responses to adult, teen, and child
versions were combined for presentation.14 The primary efficacy
end point was change in symptoms, assessed with CFQ-R-
Respiratory scores (range, 0 to 100 points; increasing scores
indicated improvement). The minimal clinically important differ-
ence (MCID) corresponds to the smallest change in symptoms
that a patient can detect and is used to interpret responses to
PROs.19,20 An MCID score of 5 was previously determined for
the CFQ-R-Respiratory Scale in stable patients.21 Thus, 5-point
changes in scores reflected improved or worsened respiratory
symptoms detected by patients.
Secondary end points included changes in pulmonary function,
hospitalizations, nonrespiratory CFQ-R scales, sputum PA den-
sity (in colony-forming units per gram sputum, log10 trans-
formed), the minimum inhibitory concentration (MIC) of aztreo-
nam for PA, the number of isolates and proportion of patients
with an aztreonam MIC  8 g/mL for PA (ie, the parenteral
breakpoint), and the prevalence of other pathogens.22
Safety Measures
Adverse events and changes in clinical laboratory values, vital
signs, and airway reactivity were monitored. Worsening CF
symptoms were treated as adverse events. Patients requiring
therapy with nonstudy antipseudomonal antibiotics discontinued
their participation in the study.
Statistical Analysis
Efficacy and safety analyses included all randomly assigned
patients receiving one or more doses of AZLI/placebo. FEV1 and
CFQ-R analyses used the last-observation-carried-forward con-
vention. Changes in FEV1 (in liters) and changes in FEV1
percent predicted were analyzed using relative values; increases
and decreases were calculated as percentages of baseline FEV1 or
FEV1 percent predicted values.
A sample size of 140 was estimated to provide 77% power to
detect an 8-point difference for change in CFQ-R-Respiratory
scores (assuming an SD of 20) and  90% power to detect a 9%
difference in FEV1 (assuming an SD of 12), with two-sided
  0.05.
Continuous variables were analyzed using analysis of covari-
ance models with treatment as the fixed effect; disease severity
(moderate/severe) and baseline values (except analysis of log10
PA colony-forming units in sputum) were covariates. At day 28,
patients were categorized as improved (a  5-point increase from
baseline CFQ-R-Respiratory scores), worse (a  5-point de-
crease from baseline), or stable/no change (a  5-point change).
These categories were analyzed with the Cochran-Mantel-Haen-
szel mean score statistic; disease severity and baseline score were
stratification variables.
Hospitalizations were analyzed using the Wilcoxon rank sum
test (days) and Fisher exact test (proportion of patients). The
aztreonam MIC inhibiting the growth of 50% of PA isolates
(MIC50) or the aztreonam MIC inhibiting the growth of 90% of
PA isolates (MIC90) and the presence of other pathogenic bacteria
were summarized (Covance Central Laboratory Services; India-
napolis, IN) as were plasma and sputum aztreonam concentra-
tions (Alta Analytical Laboratory; El Dorado Hills, CA).22 A
statistical software package (SAS, versions 8.02 and 9.1; SAS
Institute Inc; Cary, NC) was used for analyses.
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Figure 1. Study design and patient disposition.
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Results
Of the 253 patients screened, 164 began treatment
with AZLI or placebo, 138 completed 28 days of
treatment, and 124 completed the study (Fig 1). The
compliance rate for dosing ( 80% of doses) was
92%. The most common reason for discontinuation
of participation in the study during the 28-day treat-
ment period was an adverse event (ALZI group, 6
patients [7.5%]; placebo group, 13 patients [15.5%])
[Fig 1]; most of these patients (16 of 19 patients)
required treatment with nonstudy antipseudomonal
antibiotics and had symptoms indicative of pulmonary
exacerbation. The remaining three patients (all ran-
domized to receive placebo) discontinued study partic-
ipation due to hospitalizations for bowel obstruction
(n  1), for umbilical hernia requiring surgery (n  1),
or for Staphylococcus aureus bacteremia, volume de-
pletion, vancomycin-resistant Enterococcus and Pseudo-
monas septicemia, and deep vein thrombosis of the
upper left arm (n  1).
Patient Characteristics
Demographic characteristics were well balanced
between treatment groups (Table 1). The mean age
was 29.6 years. Most patients (77.4%) were  18
years of age. At baseline, mean the FEV1 was 54.6%
predicted. The concomitant medications used by
 40% patients at baseline included pancreatic en-
zymes (87%), vitamins (87%), salbutamol (79%),
dornase alfa (65%), and fluticasone propionate with
salmeterol xinafoate (40%).
Efficacy
The adjusted mean CFQ-R-Respiratory scores
increased for AZLI-treated patients and decreased
for placebo-treated patients (day 28 treatment
difference, 9.7 points; 95% confidence interval
[CI], 4.3 to 15.1; p  0.001) [Fig 2, left, Table 2].
Two weeks after treatment, scores had declined
but remained above baseline values for AZLI-
treated patients, and had continued to decline for
placebo-treated patients (day 42 treatment differ-
ence, 6.3 points; 95% CI, 1.2 to 11.4; p  0.015)
[Fig 2, left].
CFQ-R-Respiratory scores increased for AZLI-
treated patients with differing disease severities and
ages (Fig 2, right). Treatment effects were compa-
rable in magnitude for patients with moderate or
severe lung disease and were larger for younger
patients (ie, those  18 years of age).
CFQ-R-Respiratory scores improved for more
AZLI-treated patients than placebo-treated patients
(day 28;  5-point increase: AZLI group, 45 patients
[56%]; placebo group, 31 patients [37%]). Scores
also worsened for fewer AZLI-treated patients ( 5-
point decrease: AZLI group, 20 patients [25%];
placebo group, 37 patients [45%]; p  0.006 for
overall comparison).
The adjusted mean FEV1 increased for AZLI-
treated patients and decreased for placebo-treated
patients (day 28 treatment difference, 10.3%; 95%
CI, 6.3 to 14.3; p  0.001) [Fig 2, left]. Two weeks
after treatment, the mean FEV1 had declined but
remained above baseline for AZLI-treated patients,
and had continued to decline for placebo-treated
patients (day 42 treatment difference, 5.7%; 95% CI,
2.1 to 9.4; p  0.002). AZLI treatment improved








United States and Canada 63 (75.0) 62 (77.5)
Australia and New Zealand 21 (25.0) 18 (22.5)
Age,†‡ yr 31.7 (11–74) 27.4 (7–54)
Age group
 18 yr§ 16 (19.0) 21 (26.3)
 18 yr 68 (81.0) 59 (73.8)
Male gender 45 (53.6) 48 (60.0)
Weight, kg 60.7 (15.2) 59.9 (17.3)
Body mass index, kg/m2 21.9 (3.9) 21.4 (4.3)
CFTR genotype
Homozygous for F508 30 (35.7) 38 (47.5)
Heterozygous for F508 22 (26.2) 21 (26.3)
Unidentified or other 32 (38.1) 21 (26.3)
TIS¶
Courses in previous year 1.7 1.8
Courses in previous year in United
States and Canada
2.3 2.3
Dornase alfa use, % 64% 66%
FEV1, % predicted 54.8 (14.0) 54.4 (13.4)
Patients with FEV1  50%
predicted†
30 (35.7) 30 (37.5)
CFQ-R-respiratory score 60.9 (18.9) 60.5 (18.1)
MIC of aztreonam for all PA isolates
MIC50, g/mL 2 4
MIC90, g/mL 64 128
Minimum MIC, g/mL  1  1
Maximum MIC, g/mL 256  2048
Isolates tested, No. 140 128
*Values are given as the No. (%) or mean (range), unless otherwise
indicated.
†Data were obtained at screening (ie, between days  7 and  14).
‡The only significant difference (p  0.05) in demographic or base-
line characteristics between the two groups was in mean age;
patients in the AZLI group were younger. However, the proportion
of patients categorized as  18 vs  18 years of age was not
significantly different between the AZLI and placebo groups.
§Includes 15 children  6 to  12 years of age (placebo group, 4
patients; AZLI group, 11 patients).
Values are given as the mean (SD).
¶Values are given as the mean. TIS is not commercially available in
Australia and New Zealand. Two patients from these countries
reported TIS use during the previous year.
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mean FEV1 values for patients with differing lung
disease severities and ages; the subgroups had compa-
rable responses (Fig 2, right). At treatment end,
changes in CFQ-R-Respiratory scores and FEV1 were
modestly correlated (day 28 Pearson correlation coef-
ficients: AZLI group, 0.32; placebo group, 0.32).
The adjusted mean relative change in FEV1 per-
cent predicted values also increased for AZLI-
treated patients and decreased for placebo-treated
patients (day 28 treatment difference, 10.2%; 95%
CI, 6.2 to 14.2; p  0.001) and declined for both
groups after treatment (day 42 treatment difference,
5.7%; 95% CI, 2.0 to 9.4; p  0.003).
The adjusted mean sputum PA density decreased
for AZLI-treated patients and remained near base-
line for placebo-treated patients (day 28 treatment
difference,  1.453 log10 cfu/g; 95% CI,  2.1 to 
0.8; p  0.001) [Fig 2, left]. Two weeks after treat-
ment (day 42), values were near baseline values for
both treatment groups (p  0.822).
There was a trend toward fewer hospitalized pa-
tients in the AZLI group (5%) than in the placebo
group (14%; days 0 to 42; p  0.064) and toward
fewer mean hospitalization days (AZLI group, 0.5
days; placebo group, 1.5 days; p  0.049). Weight
increased 1.1% for the AZLI-treated group and 0.1%
for the placebo-treated group (day 28: 95% CI, 0.33
to 1.69; p  0.004).
The responses of AZLI-treated patients were signif-
icantly larger than those of placebo-treated patients for
6 of the 11 nonrespiratory CFQ-R scales; these scales
included Eating, Emotional Functioning, Health Per-
ceptions, Physical Functioning, Role Limitation/School
Performance, and Vitality (Table 2).
Safety
The incidence of adverse events was similar for
both groups during the AZLI/placebo treatment
period, except “productive cough” was reported by
significantly fewer AZLI-treated patients (10 pa-
tients; 12.5%) than placebo-treated patients (21 pa-
tients; 25%; p  0.047) [Table 3]. Five patients were
hospitalized during the treatment period (days 0 to
28); two patients due to respiratory symptoms (AZLI
group, one patient; placebo group, one patient), two
patients due to bowel obstruction (AZLI group, one
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Day 28: Mean Change from Baseline CFQ-R-Respiratory Scores (±SE)











Figure 2. Left: adjusted mean CFQ-R-respiratory scores, FEV1, and sputum PA density; change from baseline to study end (days 0 to
42). Child, teen, and adult responses were combined for CFQ-R-Respiratory scores. Right: change from baseline to end of treatment for
CFQ-R-Respiratory scores and FEV1; effects of age and baseline CF lung disease severity. Note that the mean change from baseline
values improved for all groups treated with AZLI and worsened for all groups treated with placebo. For all patients: AZLI group, n  80;
placebo group, n  83/84; for disease severity-moderate: AZLI group, n  50; placebo group, n  53/54; for disease severity-severe:
AZLI group, n  30; placebo group, n  30; for patient age  18 years: AZLI group, n  21; placebo group, n  16; for patient age  18
years: AZLI group, n  59; placebo group, n  67/68.
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due to umbilical hernia (placebo). Airway reactivity
(a  15% decrease in FEV1 within 30 min after
AZLI/placebo dosing at study visits) occurred in
eight patients (AZLI group, three patients; placebo
group, five patients); none withdrew for this reason.
Clinically significant changes in vital signs or mean
clinical laboratory values were not observed, except
that AZLI-treated patients trended toward fewer
shifts above the reference range for hematology
variables; these were all markers of systemic inflam-
mation. From day 14 to day 28, the percentage of
patients with shifts above the reference range for WBC
count were 11.4% and 5.3%, respectively; for neu-
trophil counts, 16.5% and 9.6%, respectively; for
neutrophil percentage, 13.6% and 7.0%, respec-
tively; and for platelets, 11.7% and 5.6%, respec-
tively, for placebo-treated and AZLI-treated pa-
tients. There were no deaths during this study and no
reports of anaphylaxis.
Clinical Pharmacology and Microbiology
Sputum and plasma aztreonam concentrations
were measured (Table 4). Throughout the study, the
aztreonam MIC50 and MIC90 values for all PA
isolates from placebo-treated patients remained un-
changed or decreased (Table 5). For AZLI-treated
patients, a transient fourfold increase in MIC90 was
observed (Table 5, day 14). The number of PA isolates
with an aztreonam MIC  8 g/mL (ie, the parenteral
breakpoint) and the proportion of patients with such
isolates did not increase during AZLI treatment.
Throughout the study, MIC50 and MIC90 values of the
other antibiotics tested (tobramycin, gentamicin, ami-
kacin, piperacillin, cefepime, meropenem, ceftazidime,
ciprofloxacin, and ticarcillin/clavulanate) for all PA iso-
lates from AZLI-treated patients remained unchanged
(ie, changes of less than fourfold) or decreased, except
for a possible persistent increase in the MIC90 value for
ticarcillin/clavulanate (increase, 256 to  256 g/mL).
There was no evidence for persistent increases in the
isolation of Stenotrophomonas maltophilia, S aureus, or
Achromobacter xylosoxidans resulting from treatment
with AZLI (Table 6). B cepacia complex was not
isolated.
Discussion
Inhaled AZLI was administered at a dose of 75
mg three times daily for 28 days to patients with
moderate-to-severe CF lung disease and PA airway
infection. These patients were receiving lower levels of
maintenance therapy than recommended in published
treatment guidelines.11 Therapy with AZLI signifi-
cantly improved respiratory symptoms and pulmonary
function, and significantly decreased sputum PA den-
sity compared with placebo. AZLI was well tolerated;
adverse events were generally consistent with symp-
toms of CF lung disease.
This was the first aerosolized antibiotic clinical
study to use a PRO as the primary efficacy end point.
Several studies10,23,24 from the past few years used
CFQ-R scales as secondary efficacy end points. In
this study, CFQ-R-Respiratory scores measured the
benefits of AZLI therapy from the patient’s perspec-
tive; the 9.7-point treatment response was larger
than the 5-point MCID score previously determined
for the CFQ-R-Respiratory Scale.13,21,25
Respiratory symptom improvements were con-
firmed by significant improvements in FEV1 and by the
following adverse event measure: compared with pla-
cebo, AZLI treatment decreased the number of reports
of “productive cough” by half. This demonstrates that




Treatment Difference* 95% CI p ValuePlacebo AZLI
Body Image 1.0 3.2 2.2  2.2–6.5 0.327
Digestion 1.9 2.2 0.3  3.5–4.0 0.889
Eating  4.7 3.6 8.4 4.1–12.7  0.001
Emotional Functioning  1.3 3.9 5.2 1.6–8.8 0.005
Health Perceptions  4.8 5.0 9.8 4.8–14.9  0.001
Physical Functioning  6.9 2.3 9.2 3.6–14.8 0.001
Respiratory Symptom  2.6 7.1 9.7 4.3–15.1  0.001
Role/School  4.2 2.1 6.4 1.3–11.4 0.014
Social Functioning  3.6  1.2 2.4  1.7–6.5 0.248
Treatment Burden  3.1 0.2 3.2  1.5–7.9 0.177
Vitality  4.4 3.6 8.0 2.5–13.5 0.005
Weight 1.4 4.7 3.3  4.0–10.5 0.376
*Comparison is based on type III sum of squares analysis of covariance models including terms for treatment group and disease severity and
CFQ-R baseline score as covariates; difference in treatments is defined as AZLI  placebo.
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patients with CF can reliably report their symptoms
using a standardized measure and provides support for
using PROs in clinical studies. However, the modest
correlation between patient-reported changes in respi-
ratory symptoms (CFQ-R-respiratory) and measured
changes in lung function (FEV1) suggests that they are
measuring different aspects of clinical efficacy; thus, a
combination of patient-reported and physiologic mea-
surements may be optimal.
In addition to respiratory symptoms, AZLI-treated
patients reported improvements in disease-related
symptoms involving eating, emotional and physical
functioning, health perceptions, role limitations/
school performance, and vitality. These results have
particular relevance for patients with a chronic ill-
ness, who must adhere to complex, time-consuming
medical regimens that affect their normal activities.
Their perception of treatment benefit is likely to
improve adherence to treatment regimens and influ-
ence their long-term health outcomes.26
CFQ-R-Respiratory scores and FEV1 increased
for AZLI-treated patients from baseline to midtreat-
ment, with little additional change to treatment end
(day 28). However, treatment effects continued to be
observed 2 weeks later. Adjusted mean PA density
decreased throughout the 28-day AZLI treatment
and returned to baseline values 2 weeks later. These
results support the 28-day AZLI treatment period,
which was extended from the 14-day treatment
period utilized in a previous study.27
Only 15 patients (9.1%) in this study were children
(ie, 6 to 12 years of age). For the analyses presented
herein, they were combined with adolescent patients
to give a group of 37 patients (22.6%) who were  18
years of age. The mean improvement in the CFQ-R-
Respiratory score was larger for these younger patients
than for older patients. There was no apparent effect of
age on improvement in lung function (FEV1).
Compared with patients in a previous 28-day AZLI
study,10 patients in this study had received fewer
courses of TIS during the previous year (mean
number of courses, 1.8 vs 5.3, respectively), and at
study entry fewer patients in this study were using
dornase alfa (65% vs 85%, respectively) or azithro-
mycin (0% [specified by entry criteria] vs 70%,
respectively). Patients in both AZLI studies had
comparable lung function (FEV1,  25% to  75%
predicted values). The lower levels of maintenance
therapy received by patients in the study described
herein may reflect a number of factors, as follows:
patient intolerance to available therapies; lack of
clinical response to specific therapies; clinician and
patient preferences; or the difficulty of obtaining TIS
in some countries participating in the study (TIS is
not commercially available in New Zealand or Aus-
tralia). The treatment effects observed for these less
intensively treated patients were larger than those
observed in the previous AZLI study10 and approached
those observed in the original TIS studies28,29 a decade
ago. However, the population in the AZLI study de-
scribed herein was on average, 8 years older, with a
bacterial sputum density approximately 10-fold less,
and baseline FEV1 percent predicted values 4 to 5%
higher than those for the population enrolled in the
original TIS studies.28 These baseline differences likely
reflect the improved clinical management of CF that
has been developed over the past decade.1–5 Patient
compliance with TID dosing was high in the study
described herein, it will also be interesting to assess
patient compliance and treatment efficacy for the
Table 4—Aztreonam Concentrations in Sputum and





Sputum: 10 min after dosing, g/g sputum
Day 0 (baseline visit) 530 8–6,010 74
Day 14 (midtreatment visit) 677 2–2,780 67
Day 28 (end-of-treatment visit) 451 1.0–2,800 63
Plasma: 1 h after dosing, ng/mL
Day 0 (baseline visit) 495 0–1,620 72
Day 14 (midtreatment visit) 595 12–1,660 76
Day 28 (end-of-treatment visit) 603 0–1,740 68
Table 3—Treatment-Emergent Adverse Events
Reported by > 5% Patients in Either Treatment Group






Cough 25 (29.8) 28 (35.0)
Productive cough‡ 21 (25.0) 10 (12.5)
Pharyngolaryngeal pain 7 (8.3) 10 (12.5)
Nasal congestion 8 (9.5) 8 (10.0)
Pyrexia 4 (4.8) 7 (8.8)
Crackles in lung 6 (7.1) 6 (7.5)
Headache 10 (11.9) 5 (6.3)
Dyspnea 8 (9.5) 5 (6.3)
Wheezing 7 (8.3) 5 (6.3)
Chest discomfort 4 (4.8) 5 (6.3)
Throat irritation 2 (2.4) 5 (6.3)
Fatigue 7 (8.3) 3 (3.8)
Pulmonary function test decreased 6 (7.1) 3 (3.8)
Abdominal pain 6 (7.1) 2 (2.5)
Hemoptysis 6 (7.1) 2 (2.5)
*Values are given as No. (%). TEAE  treatment-emergent adverse
event.
†TEAEs were coded using the Medical Dictionary for Regulatory
Activities (MedDRA, version 8.0) preferred term.
‡Significantly fewer patients in the AZLI group (p  0.047 	Fisher
exact test
); tested whether TEAE incidence was  10% in either
treatment group.
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twice-a-day and three-times-a-day dosing groups in the
ongoing 18-month AZLI study.
This study was designed to assess the short-term
efficacy of AZLI and to provide a rationale for a
long-term trial to evaluate its use as suppressive
therapy in patients with chronic PA infection.
Existing long-term therapies used in patients with
CF have typically been assessed in controlled trials
with a duration of 6 months.23,28,30 An open-label,
18-month clinical trial31 of AZLI (intermittent treat-
ment every other month) is ongoing to address the
efficacy and safety of long-term suppressive therapy.
The use of AZLI by clinicians will need to be
guided by the results of the two completed phase III
studies with regard to the patient’s level of lung
function, sputum microbiology, and tolerance of in-
haled therapy and existing therapies. AZLI may
provide an important new therapy for patients with
CF who have moderate-to-severe lung disease. Since
the improvement in respiratory symptoms and FEV1
can be easily monitored and measured in a short
time period, a 28-day trial of therapy may be an
appropriate method of assessing the value of AZLI
therapy in an individual patient. Possible clinical
strategies may include using AZLI in rotation with
other inhaled antibiotics and/or in combination with
other nonantibiotic therapies. However, further
studies will be needed to define the appropriate
strategy for incorporating AZLI use into the long-
term treatment of chronic PA airway infection.
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Appendix: Participating Study Sites, Site
Investigators, and Study Research
Coordinators for the AIR-CF1 Trial
Australia
Alfred Hospital, Melbourne, VIC; Site Investigator (SI): John
Wilson; Research Coordinator (RC): Denise Clark.
Princess Margaret Hospital for Children, Perth, WA; SI: Tonia
Douglas; RC: Charlotte Allen.
Royal Adelaide Hospital, Adelaide, SA; SI: Hugh Greville; RC:
Kirsty Herewane.
Royal Children’s Hospital, Herston, Brisbane, QLD; SI: Claire
Wainwright; RC: Aaron Buckner.
Sir Charles Gairdner Hospital, Perth, WA; SI: Gerard Ryan;
RC: Kerry Boughton.
The Children’s Hospital at Westmead, Sydney, NSW; SI: Peter
J. Cooper; RC: Karen McKay.
Westmead Hospital, Sydney, NSW; SI: Peter Middleton; RC:
Karen Bovington.
Table 6—Treatment-Emergent Isolation of Other
Organisms*







Treatment-emergent S aureus 7 (8.6) 4 (5.4)
intermittent isolation B cepacia 0 0
S maltophilia 3 (3.7) 3 (4.1)
A xylosoxidans 2 (2.5) 0
Treatment-emergent S aureus 5 (6.2) 2 (2.7)
persistent isolation B cepacia 0 0
S maltophilia 0 2 (2.7)
A xylosoxidans 2 (2.5) 1 (1.4)
*Values are given as No. (%). Intermittent isolation  organism not
isolated at day 0 but isolated once between days 0 and 42, and not
a persistent isolation; persistent isolation  organism not isolated at
day 0 but isolated in at least two subsequent specimens or at the
early termination visit.
†Data available for 81 of 84 patients.
‡Data available for 74 of 80 patients.











Placebo group (n  84)
Day 0 2 64 140  1 256
Day 14 2 64 128  1 512 No No
Day 28 2 64 116  1 256 No No
Day 42 2 32 94  1  2,048 No No
AZLI group (n  80)
Day 0 4 128 128  1  2,048
Day 14 4 512 118  1  2,048 No Increased
Day 28 8 128 102  1  2,048 No No
Day 42 4 128 113  1 2,048 No No
*A change of fourfold or more was considered to be an increase/decrease in MIC.
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Canada
Centre Hospitalier de l‘Université de Montreal (CHUM),
Montreal, QC; SI: Yves Berthiaume; RC: Nadia Beaudoin.
Children’s Hospital of Western Ontario, London, ON; SI:
Brian Lyttle; RC: Anne-Marie Lyttle.
Queen Elizabeth II Health Sciences Centre, Halifax, NS; SI:
Roger T. Michael; RC: Andrea Dale.
St. Paul’s Hospital, Vancouver, BC; SI: Pearce Wilcox; RC:
Georgina Lopez.
University of Alberta, Edmonton, AB; SI: Peter Zuberbuhler;
RCs: Josette Salgado and Joan Tabak.
New Zealand
Greenlane Clinical Centre and Starship Children’s Health
Centre, Auckland; SI: John Kolbe; RC: Wendy Fergusson.
United States
Alamo Clinical Research Associates, San Antonio, TX; SI: Peter
Fornos; RC: Terri Phillips.
Albany Medical College, Albany, NY; SI: Jonathan Rosen; RC:
Katharine Mokhiber.
Baylor Research Institute, Dallas, TX; SI: Mark Millard; RC:
Kim Waters.
Capital Allergy and Respiratory Disease Center, Sacramento,
CA; SI: Bradley Chipps; RC: Bryce Autret.
Central Maine Pulmonary Associates, Lewiston, ME; SI: Ralph
Harder; RC: Rachel Barry.
Children’s Hospital Los Angeles, Los Angeles, CA; SI: Marlyn
Woo; RC: Lynn Fukushima.
Children’s Hospital of Orange County, Orange, CA; SI: Bruce
Nickerson; RC: Luis Valdez.
Children’s Hospital of Pittsburgh, Pittsburgh, PA; SI: Joseph
Pilewski; RCs: Judy Fulton, Elizabeth Hartigan, and Sandra
Hurban.
Childrens Lung Specialists, Las Vegas, NV; SI: Craig Nakamura;
RC: Tara Brascia.
Children’s Memorial Hospital and Northwestern University,
Chicago, IL; SI: Susanna McColley; RC: Catherine Powers.
Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH; SIs: Bruce Trapnell and Cori Daines; RC: Lorrie Duan.
Long Island Jewish Medical Center, New Hyde Park, NY; SI:
Rubin Cohen; RC: Maryanne Gannon.
Louisiana State University Health Sciences Center, Shreve-
port, LA; SI: Kimberly Jones; RC: Antoinette Gardner.
Medical College of Georgia, Augusta, GA; SI: Margaret Guill;
RC: Julie C. Hall.
Miller Children’s Hospital and Long Beach Memorial Hospi-
tal, Long Beach, CA; SI: Terry Chin; RC: Mariam Ischander.
Naval Medical Center, Portsmouth, VA; SI: Rees Lee; RC:
Adrienne Espinosa.
Nemours Children’s Clinic, Orlando, FL; SI: Mark Weatherly;
RC: Sondra Sadler.
Pediatric Breathing Disorders Clinic, Anchorage, AK; SI: Dion
Roberts; RC: Vicki Roberts.
Pediatric Pulmonary Associates, Columbia, SC; SI: Daniel
Brown; RC: Carolyn Turner.
Phoenix Children’s Hospital, Phoenix, AZ; SI: Peggy Radford;
RCs: Natalia Argel and Annette Szpiszar Gong.
Riley Hospital for Children, Indianapolis, IN; SI: Michelle
Howenstine; RCs: Mary Blagburn and Delana Terrill.
St. Barnabas Healthcare System, Livingston, NJ; SI: Dorothy
Bisberg; RC: Carol Epstein.
St. Louis University, St Louis, MO; SI: Ravi Nayak; RC:
Jennifer Dizes.
State University of New York (SUNY) Upstate Medical Uni-
versity, Syracuse, NY; SI: Ran Anbar; RC: Donna Lindner.
Tulane University Health Sciences Center, New Orleans, LA;
SI: Blesilda Quiniones; RC: Melanie Larrieu.
University of Alabama at Birmingham, Birmingham, AL; SI: JP
Clancy; RC: Ginger Reeves.
University of Arkansas for Medical Sciences, Little Rock, AR;
SI: Paula Anderson; RC Adam Taggart.
University of Florida Health Sciences Center, Gainesville, FL;
SI: L. Terry Spencer; RC: Dawn Baker.
University of Iowa, Iowa City, IA; SI: Richard Ahrens; RC:
Mary Teresi.
University of Michigan, Ann Arbor, MI; SI: Samya Nasr; RC:
Ermee Sakmar.
University of Missouri, Columbia, MO; SI: Peter Konig; RC:
Donna M. Smith.
University of North Carolina at Chapel Hill, Chapel Hill, NC;
SI: George Z. Retsch-Bogart; RC: Carol Woody-Barlow.
University of Pennsylvania Health System, Philadelphia, PA;
SI: Denis Hadjiliadis; RC: Barbara Finkel.
University of Utah, Salt Lake City, UT; SI: Theodore Liou; RC:
Kristyn Packer.
University of Washington Medical Center, Seattle, WA; SI:
Moira Aitken; RC: Sharon McNamara.
University of Wisconsin, Madison, WI; SI: James Runo; RC:
Sharen Wilson.
University of Mississippi Medical Center, Jackson, MS; SI:
Fadel Ruiz; RC: Kim Adcock.
Via Christi Regional Medical Center, St. Francis Campus,
Wichita, KS; SI: Maria Riva; RC: Janet Messamore.
Virginia Commonwealth University, Richmond, VA; SI: Greg
Elliott; RC: Juellisa Gadd.
Yale-New Haven Hospital, New Haven, CT; SI: John R.
McArdle; RC: Kathryn Engle.
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